v3.26.3
Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Income Statement [Abstract]    
Revenues $ 759 $ 316
Cost of revenues (339) (201)
Gross profit 420 115
Operating expenses:    
Research and development expenses (2,825) (3,961)
Acquired IPR&D related to the Fishway Transaction (10,915)
Less: participation by the National Institute of Allergy and Infectious Diseases, the IIA (each as defined below) and Horizon Europe 72 30
Research and development expenses, net (13,668) (3,931)
General and administrative expenses (2,321) (2,534)
Operating loss (15,569) (6,350)
Other financial income, net 415 439
Interest expenses related to the Loan (defined below) (226) (229)
Total financial income, net 189 210
Loss before taxes (15,380) (6,140)
Income benefit (taxes) (12) 8
Net loss (15,392) (6,132)
Net loss attributed to non-controlling interest (5,002) (282)
Net loss attributed to shareholders $ (10,390) $ (5,850)
Loss per share:    
Basic loss per share (in Dollars per share) $ (0.85) $ (0.65)
Diluted loss per share (in Dollars per share) $ (0.85) $ (0.65)
Weighted average number of shares used in computing basic loss per share (in Shares) 12,176,867 8,995,635
Weighted average number of shares used in computing diluted loss per share (in Shares) 12,176,867 8,995,635